KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression. PMID 38241514 · Chronic Obstr Pulm Dis · 2024-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neo-Adjuvant Therapy for Metastatic Melanoma. PMID 38610925 · Cancers (Basel) · 2024-Mar-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. PMID 38560970 · Hematol Oncol Stem Cell Ther · 2024-Mar-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. PMID 38509517 · Trials · 2024-Mar-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Diaphragmatic Initiated Ventilatory Assist (DIVA) trial: study protocol for a randomized controlled trial comparing rates of extubation failure in extremely premature infants undergoing extubation to non-invasive neurally adjusted ventilatory assist versus non-synchronized nasal intermittent positive pressure ventilation. PMID 38509583 · Trials · 2024-Mar-20 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. PMID 38181323 · J Clin Oncol · 2024-Mar-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial. PMID 37963313 · J Clin Oncol · 2024-Mar-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview. PMID 38423814 · Vaccine · 2024-Mar-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Appropriate Prescribing for older adults with Multimorbidity (Pro-M): protocol for a feasibility study. PMID 38500190 · Arch Public Health · 2024-Mar-18 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Correction: Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). PMID 38491488 · Trials · 2024-Mar-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial. PMID 38463808 · Heliyon · 2024-Mar-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. PMID 37950894 · Br J Dermatol · 2024-Mar-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis. PMID 38486276 · J Ovarian Res · 2024-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials. PMID 37541785 · J Neurol Neurosurg Psychiatry · 2024-Mar-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial. PMID 38475765 · BMC Cancer · 2024-Mar-12 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial. PMID 38468320 · Trials · 2024-Mar-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. PMID 38467646 · Nat Commun · 2024-Mar-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial. PMID 38454345 · BMC Cancer · 2024-Mar-07 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT). PMID 38299867 · Microbiol Spectr · 2024-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. PMID 38546648 · JAMA Netw Open · 2024-Mar-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. PMID 38536173 · JAMA Netw Open · 2024-Mar-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. PMID 38439079 · Breast Cancer Res · 2024-Mar-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 6 Panel · risk visible
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. PMID 38433233 · BMC Psychiatry · 2024-Mar-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. PMID 38262444 · Oncologist · 2024-Mar-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. PMID 38430375 · Cancer Immunol Immunother · 2024-Mar-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 6 Panel · risk visible
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study. PMID 38243752 · Hum Reprod · 2024-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial. PMID 38150215 · JAMA Surg · 2024-Mar-01 The study is a randomized Phase 3 trial in oncology (breast cancer) reporting original results, but it compares surgical localization devices (paramagnetic seed vs. guidewire) with superparamagnetic iron oxide for sentinel lymph node detection. It does not involve a therapeutic drug intervention, and the primary outcomes are procedural (re-excision rate, resection ratio), not time-to-event efficacy endpoints like OS or PFS. Therefore, it does not meet the inclusion criteria for drug intervention and time-to-event endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria. PMID 38110196 · Clin J Am Soc Nephrol · 2024-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Single-Fraction Versus Fractionated Preoperative Radiosurgery for Resected Brain Metastases: A PROPS-BM International Multicenter Cohort Study. PMID 37717787 · Int J Radiat Oncol Biol Phys · 2024-Mar-01 The report is an original oncology study with human subjects and time-to-event endpoints, but it is not eligible because it is not a randomized controlled trial (it's a retrospective cohort study), does not involve a drug-containing intervention (it compares fractionation schedules of radiosurgery), and does not represent a Phase III randomized trial (the Phase III trial mentioned is ongoing, not the subject of this report).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
START CARE: a protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children. PMID 38590934 · ERJ Open Res · 2024-Mar 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab. PMID 38500798 · ERJ Open Res · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. PMID 38485863 · Dermatol Ther (Heidelb) · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review. PMID 38466535 · Target Oncol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC. PMID 38455595 · JTO Clin Res Rep · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum: Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority phase III trail. PMID 38450310 · Chronic Dis Transl Med · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial. PMID 38445295 · World Allergy Organ J · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution. PMID 38437701 · Ann Intern Med · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN Study. PMID 38434770 · JTO Clin Res Rep · 2024-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Correction to: "Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial". PMID 38407505 · Headache · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial. PMID 38403865 · Infect Dis Ther · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study. PMID 38402467 · Hematol Oncol · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. PMID 38391212 · J Eur Acad Dermatol Venereol · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. PMID 38367705 · J Infect · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial. PMID 38356731 · EClinicalMedicine · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3 Prospective Randomized Trial to Evaluate the Impact of Augmented Reality During Robot-assisted Radical Prostatectomy on the Rates of Postoperative Surgical Margins: A Clinical Trial Protocol. PMID 38333626 · Eur Urol Open Sci · 2024-Mar 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). PMID 38329052 · J Urol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass). PMID 38313139 · Lancet Reg Health Eur · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis. PMID 38310163 · Diabetes Ther · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. PMID 38309015 · Eur J Cancer · 2024-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer. PMID 38306841 · Eur J Cancer · 2024-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed